

**S4 Table.** Baseline characteristics of patients with stage IV adenocarcinoma in 2015

	Total	Non-survivor	Survivor	p-value
No. of patients	348	310	38	
Male sex	212 (60.9)	192 (61.9)	20 (52.6)	0.267
Age (yr)	69.0 (59.0-75.0)	70.0 (59.8-76.0)	62.0 (56.0-72.3)	0.058
Ever-smoker	181 (52.0)	163 (52.6)	18 (47.4)	0.518
BMI (kg/m <sup>2</sup> )	21.0 (20.2-21.7)	20.9 (20.0-21.6)	22.1 (19.7-24.3)	0.300
Symptoms	342	305	37	
Asymptomatic	22 (6.4)	19 (6.2)	3 (8.1)	0.673
Cough	120 (35.1)	109 (35.7)	11 (29.7)	0.447
Sputum	53 (15.5)	47 (15.4)	6 (16.2)	0.919
Dyspnea	93 (27.2)	85 (27.9)	8 (21.6)	0.403
Hoarseness	9 (2.6)	7 (2.3)	2 (5.4)	0.271
Hemoptysis	10 (2.9)	9 (3.0)	1 (2.7)	0.925
Weight loss	26 (7.6)	24 (7.9)	2 (5.4)	0.583
Pain	92 (26.9)	87 (28.5)	5 (13.5)	0.049
Performance status	255	225	30	0.162
0-1	216 (84.7)	188 (83.6)	28 (93.3)	
2-4	39 (15.3)	37 (16.4)	2 (6.7)	
EGFR	118/304 (38.8)	101/270 (37.4)	17/34 (50.0)	0.328
ALK	19/233 (8.2)	12/209 (5.7)	7/24 (29.2)	<0.001

Values are presented as the number (%) or median (interquartile range). ALK, anaplastic lymphoma kinase; BMI, body mass index; EGFR, epidermal growth factor receptor.